

ACO Name and Location

CHI Continuum LLC
2525 Court Drive
Gastonia, NC 28054

ACO Primary Contact

Tod Erickson
704-834-4532
Tod.erickson@caromonthhealth.org

Organizational Information

ACO Participants:

ACO Participants	ACO Participant in Joint Venture
CaroMont Medical Group, Inc.	N

ACO Governing Body:

Member Last Name	Member First Name	Member Title/Position	Member's Voting Power (Expressed as a percentage or number)	Membership Type	ACO Participant Legal Business Name and D/B/A, if applicable
Dyksterhouse	Andrew	Dr.	25	ACO Participant	CaroMont Medical Group Inc.
Besson	Kathleen	Ms.	20	ACO Participant	CaroMont Medical Group Inc.
Miller	Rachel	Dr.	15	ACO Participant	CaroMont Medical Group Inc.
O'Connor	David	Mr.	20	ACO Participant	CaroMont Medical Group Inc.
Davis	Todd	Dr.	15	ACO Participant	CaroMont Medical Group Inc.
Williams	Johnathan	Dr.	15	ACO Participant	CaroMont Medical Group, Inc.
Trimmer	Mary	Ms.	15	Medicare Beneficiary	N/A.

Key ACO Clinical and Administrative Leadership:

ACO Executive: Chris Peek

Medical Director: Dr. Todd Davis

Compliance Officer: Cathy Jorgensen

Quality Assurance/Improvement Officer: Cindy Burton, RN, BSN

Associated Committees and Committee Leadership:

Committee Name	Committee Leader Name and Position
Quality Assurance and Improvement Committee	Dr. Andrew Dyksterhouse, Chair
Compliance Committee	Ms. Cathy Jorgensen, Compliance Officer

Physician Leadership Council	Dr. Andrew Dyksterhouse, Chair
Finance and Operations Committee	Dr. Harry Caulfield, Chair

Types of ACO Participants, or Combinations of Participants, That Formed the ACO:

- ACO professionals in a group practice arrangement
- Partnerships or joint venture arrangements between hospitals and ACO professionals
- Networks of individual practices of ACO professionals

Shared Savings and Losses

Amount of Shared Savings/Losses:

- Third Agreement Period
 - Performance Year 2020, \$3,101,386
- Second Agreement Period
 - Performance Year 2019, \$1,821,806
 - Performance Year 2018, \$0
 - Performance Year 2017, \$0
- First Agreement Period
 - Performance Year 2016, \$5,146,102
 - Performance Year 2015, \$3,784,257
 - Performance Year 2014, \$2,590,837

Shared Savings Distribution:

- Third Agreement Period
 - Performance Year 2020
 - Proportion invested in infrastructure: 2.1%
 - Proportion invested in redesigned care processes/resources: 23.8%
 - Proportion of distribution to ACO participants: 74.1%
- Second Agreement Period
 - Performance Year 2019
 - Proportion invested in infrastructure: 0.6%
 - Proportion invested in redesigned care processes/resources: 38.6%
 - Proportion of distribution to ACO participants: 60.8%
 - Performance Year 2018
 - Proportion invested in infrastructure: N/A
 - Proportion invested in redesigned care processes/resources: N/A
 - Proportion of distribution to ACO participants: N/A
 - Performance Year 2017

- Proportion invested in infrastructure: N/A
- Proportion invested in redesigned care processes/resources: N/A
- Proportion of distribution to ACO participants: N/A

- First Agreement Period
 - Performance Year 2016
 - Proportion invested in infrastructure: 6%
 - Proportion invested in redesigned care processes/resources: 2%
 - Proportion of distribution to ACO participants: 92%
 - Performance Year 2015
 - Proportion invested in infrastructure: 11%
 - Proportion invested in redesigned care processes/resources: 3%
 - Proportion of distribution to ACO participants: 86%
 - Performance Year 2014
 - Proportion invested in infrastructure: 6%
 - Proportion invested in redesigned care processes/resources: 5%
 - Proportion of distribution to ACO participants: 89%

Quality Performance Results

2020 Quality Performance Results:

ACO Quality Measure Number	Measure Name	Rate	ACO Mean
ACO-43	Ambulatory Sensitive Condition Acute Composite (AHRQ Prevention Quality Indicator (PQI #91)	1.17	0.95
ACO-13	Falls: Screening for Future Fall Risk	98.23	84.97
ACO-14	Preventive Care and Screening: Influenza Immunization	92.67	76.03
ACO-17	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	95.00	81.67
ACO-18	Preventive Care and Screening: Screening for Depression and Follow-up Plan	89.92	71.46

ACO-19	Colorectal Cancer Screening	85.10	72.59
ACO-20	Breast Cancer Screening	84.93	74.05
ACO- 42	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	87.60	83.37
ACO-27	Diabetes Mellitus: Hemoglobin A1c Poor Control	9.73	14.70
ACO-28	Hypertension (HTN): Controlling High Blood Pressure	78.77	72.87

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low sample size. The Centers for Medicare & Medicaid Services (CMS) also waived the requirement for ACOs to field a CAHPS for ACOs survey for PY 2020 through the Physician Fee Schedule Final Rule for Calendar Year 2021. Additionally, CMS reverted ACO-8 Risk-Standardized, All Condition Readmission and ACO-38 Risk-Standardized Acute Admission Rates for Patients with Multiple Chronic Conditions to pay-for-reporting, given the impact of the coronavirus disease 2019 (COVID-19) public health emergency (PHE) on these measures.”

For Previous Years’ Financial and Quality Performance Results, Please Visit data.cms.gov

Payment Rule Waivers

- Skilled Nursing Facility (SNF) 3-Day Rule Waiver:
 - Our ACO uses the SNF 3-Day Rule Waiver, pursuant to 42 CFR § 425.612.
- Waiver for Payment for Telehealth Services:
 - Our ACO clinicians provide telehealth services using the flexibilities under 42 CFR § 425.612(f) and 42 CFR § 425.613.

Fraud and Abuse Waivers

- **ACO Pre-Participation Waiver:**

The following information describes each arrangement for which our ACO seeks protection under the ACO Pre-Participation Waiver, including any material amendment or modification to a disclosed arrangement.

N/A

- **ACO Participation Waiver:**

The following information describes each arrangement for which our ACO seeks protection under the ACO Participation Waiver, including any material amendment or modification to a disclosed arrangement.

N/A

